FIRE Funds Income Target ETF FIRI 深 沪
已收盘 10-24 16:00:00 美东时间
18.9449
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 18.9449
- 总市值 123.14万
- 52周最高 19.115
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 17.6612
- 委 比 0.00%
- 总股本 6.50万
- 历史最高 18.1637
- 量 比 0
- 振 幅 0.00%
- 历史最低 17.7417
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate
05-04 21:02
Cardiff Oncology To Present Updated Data From CRDF-004 In Participants With First-Line RAS-Mutated Metastatic Colorectal Cancer At 2026 American Society Of Clinical Oncology
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, a randomized
04-21 22:06
Caris Life Sciences Launches AI-Driven Pancreatic Cancer Signature To Guide First-Line Treatment In Pancreatic Ductal Adenocarcinoma
Caris AI Insights are proprietary and only available to Caris Life Sciences customersIRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric,
03-09 20:39
Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
Earnings Call Insights: Revolution Medicines (RVMD) Q4 2025 Management View CEO Mark Goldsmith emphasized "substantial progress and growing momentum for our pioneering RAS(ON) inhibitor pipeline and o...
02-26 10:18
Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment
Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation.
02-26 02:22
Pfizer Announces Topline PFS Survival Results From Cohort 3, Separate Randomized Cohort Of Pivotal BREAKWATER Trial, Evaluating BRAFTOVI In Combination With Cetuximab And FOLFIRI In mCRC With BRAF V600E Mutation
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal cancerResults reinforce potential of
02-17 19:48
Pfizer Reports BRAFTOVI Regimen Improves Progression-Free Survival in BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Reports BRAFTOVI Regimen Improves Progression-Free Survival in BRAF V600E-Mutant Metastatic Colorectal Cancer Pfizer Inc. announced positive topline results from Cohort 3 of the pivotal Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab and FOLFIRI in pat
02-17 19:45
FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer
FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer Oncolytics Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to pelareorep in combination with bevacizumab (Avastin®) and FOL
02-04 21:50
Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC
Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC Cardiff Oncology Inc. announced positive interim results from its randomized Phase 2 clinical trial (CRDF-004) evaluating onvansertib in combination with standard of care regimens (FOLFIRI/bevacizumab or
01-28 01:11
BUZZ-Street View: Brokerages positive on GE Vernova's 2028 targets
Updates ** Brokerages raise PT on power-equipment maker GE Vernova GEV.N as co forecast higher revenue for 2026 on Tuesday on the back of strong demand ** Shares climb 10.2% to $688.6 before the bell,...
2025-12-10 20:22
